126 related articles for article (PubMed ID: 38417139)
1. ATPase Copper Transporting Beta (ATP7B) Is a Novel Target for Improving the Therapeutic Efficacy of Docetaxel by Disulfiram/Copper in Human Prostate Cancer.
Song L; Nguyen V; Xie J; Jia S; Chang CJ; Uchio E; Zi X
Mol Cancer Ther; 2024 Jun; 23(6):854-863. PubMed ID: 38417139
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK
Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734
[TBL] [Abstract][Full Text] [Related]
3. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
[TBL] [Abstract][Full Text] [Related]
4. Clusterin and COMMD1 independently regulate degradation of the mammalian copper ATPases ATP7A and ATP7B.
Materia S; Cater MA; Klomp LW; Mercer JF; La Fontaine S
J Biol Chem; 2012 Jan; 287(4):2485-99. PubMed ID: 22130675
[TBL] [Abstract][Full Text] [Related]
5. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts.
Nakagawa T; Inoue Y; Kodama H; Yamazaki H; Kawai K; Suemizu H; Masuda R; Iwazaki M; Yamada S; Ueyama Y; Inoue H; Nakamura M
Oncol Rep; 2008 Aug; 20(2):265-70. PubMed ID: 18636185
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of cancer cells towards Cisplatin and Carboplatin by protein kinase D inhibitors through modulation of ATP7A/B (copper transport ATPases).
Janardhanan P; Somasundaran AK; Balakrishnan AJ; Pilankatta R
Cancer Treat Res Commun; 2022; 32():100613. PubMed ID: 35908410
[TBL] [Abstract][Full Text] [Related]
8. Distinct Wilson's disease mutations in ATP7B are associated with enhanced binding to COMMD1 and reduced stability of ATP7B.
de Bie P; van de Sluis B; Burstein E; van de Berghe PV; Muller P; Berger R; Gitlin JD; Wijmenga C; Klomp LW
Gastroenterology; 2007 Oct; 133(4):1316-26. PubMed ID: 17919502
[TBL] [Abstract][Full Text] [Related]
9. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
[TBL] [Abstract][Full Text] [Related]
10. Roles of COMM-domain-containing 1 in stability and recruitment of the copper-transporting ATPase in a mouse hepatoma cell line.
Miyayama T; Hiraoka D; Kawaji F; Nakamura E; Suzuki N; Ogra Y
Biochem J; 2010 Jul; 429(1):53-61. PubMed ID: 20433422
[TBL] [Abstract][Full Text] [Related]
11. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
12. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
[TBL] [Abstract][Full Text] [Related]
13. Copper signaling axis as a target for prostate cancer therapeutics.
Safi R; Nelson ER; Chitneni SK; Franz KJ; George DJ; Zalutsky MR; McDonnell DP
Cancer Res; 2014 Oct; 74(20):5819-31. PubMed ID: 25320179
[TBL] [Abstract][Full Text] [Related]
14. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Gao Q; Zheng J
Biomed Pharmacother; 2018 Jan; 97():528-534. PubMed ID: 29091904
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
16. Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin.
Miyashita H; Nitta Y; Mori S; Kanzaki A; Nakayama K; Terada K; Sugiyama T; Kawamura H; Sato A; Morikawa H; Motegi K; Takebayashi Y
Oral Oncol; 2003 Feb; 39(2):157-62. PubMed ID: 12509969
[TBL] [Abstract][Full Text] [Related]
17. Clusterin (apolipoprotein J), a molecular chaperone that facilitates degradation of the copper-ATPases ATP7A and ATP7B.
Materia S; Cater MA; Klomp LW; Mercer JF; La Fontaine S
J Biol Chem; 2011 Mar; 286(12):10073-83. PubMed ID: 21242307
[TBL] [Abstract][Full Text] [Related]
18. The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin.
Safaei R; Adams PL; Maktabi MH; Mathews RA; Howell SB
J Inorg Biochem; 2012 May; 110():8-17. PubMed ID: 22459168
[TBL] [Abstract][Full Text] [Related]
19. Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells.
Kalayda GV; Wagner CH; Buss I; Reedijk J; Jaehde U
BMC Cancer; 2008 Jun; 8():175. PubMed ID: 18565219
[TBL] [Abstract][Full Text] [Related]
20. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu M; Sumizawa T; Mutoh M; Chen ZS; Terada K; Furukawa T; Yang XL; Gao H; Miura N; Sugiyama T; Akiyama S
Cancer Res; 2000 Mar; 60(5):1312-6. PubMed ID: 10728692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
